ATP-mediated kinome selectivity: The missing link in understanding the contribution of individual JAK kinase isoforms to cellular signaling

ACS Chemical Biology

Volumn 9, Issue 7, 2014, Pages 1552-1558

  Thorarensen, Atli ^a   Banker, Mary Ellen ^a   Fensome, Andrew ^a   Telliez, Jean Baptiste ^a   Juba, Brian ^a   Vincent, Fabien ^a   Czerwinski, Robert M ^a   Casimiro Garcia, Agustin ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; INTERLEUKIN 15; INTERLEUKIN 2; JANUS KINASE; JANUS KINASE INHIBITOR; NIBR 3049; UNCLASSIFIED DRUG; WYE 151650; ISOPROTEIN; JANUS KINASE 1; JANUS KINASE 3; PROTEIN KINASE INHIBITOR; STAT5 PROTEIN;

ARTICLE; CELL ACTIVITY; CELL ASSAY; CELL FUNCTION; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; INTRACELLULAR SIGNALING; PRIMARY CELL; PRIORITY JOURNAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; HUMANS; JANUS KINASE 1; JANUS KINASE 3; JANUS KINASES; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 84904570393     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb5002125     Document Type: Article

References (28)

1. Knapp, S., Arruda, P., Blagg, J., Burley, S., Drewry, D. H., Edwards, A., Fabbro, D., Gillespie, P., Gray, N. S., Kuster, B., Lackey, K. E., Mazzafera, P., Tomkinson, N. C., Willson, T. M., Workman, P., and Zuercher, W. J. (2013) A public-private partnership to unlock the untargeted kinome Nat. Chem. Biol. 9, 3-6
2. Cohen, P. and Alessi, D. R. (2013) Kinase Drug Discovery-What's Next in the Field? ACS Chem. Biol. 18, 96-104
3. Dar, A. C. and Shokat, K. M. (2011) The evolution of protein kinase inhibitors from antagonist to agonist of cellular signaling Annu. Rev. Biochem. 80, 769-795
4. Backes, A. C., Zech, B., Felber, B., Klebl, B., and Müller, G. (2008) Small-molecular inhibitors binding to protein kinases. Part I: Exceptions from the traditional pharmacophore approach of type I inhibition Expert Opin. Drug Discovery 3, 1409-1425
5. Backes, A. C., Zech, B., Felber, B., Klebl, B., and Müller, G. (2008) Small-molecular inhibitors binding to protein kinases. Part II: The novel pharmacophore approach of type II and type III inhibition Expert Opin. Drug Discovery 3, 1427-1449
6. Brandt, P., Jensen, A. J., and Nilsson, J. (2009) Small kinase assay panels can provide a measure of selectivity Bioorg. Med. Chem. Lett. 19, 5861-5863
7. Posy, S. L., Hermsmeier, M. A., Vaccaro, W., Ott, K.-H., Todderud, G., Lippy, J. S., Trainor, G. L., Loughney, D. A., and Johnson, S. R. (2011) Trends in kinase selectivity: insights for target class-focused library screening J. Med. Chem. Lett. 54, 54-66
8. Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., and Peterson, J. R. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nat. Biotechnol. 29, 1039-1046
9. Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., and Zarrnkar, P. P. (2011) Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29, 1046-1052
10. Graczyk, P. P. (2007) Gini coefficient: A new way to express selectivity of kinase inhibitors against a family of kinases J. Med. Chem. 5773-5779 (Pubitemid 350106032)
11. Cheng, A. C., Eksterowicz, J., Geuns-Meyer, S., and Sun, Y. (2010) Analysis of kinase inhibitor selectivity using a thermodynamics-based partition index J. Med. Chem. 53, 4502-4510
12. Laurence, A., Pesu, M., Silvennoinen, O., and O'Shea, J. (2012) JAK kinases in health and disease: an update Open Rheumatol. J. 6, 232-244
13. Norman, P. (2012) Selective JAK1 inhibitor and selective TYK2 inhibitor patents Expert Opin. Ther. Pat. 22, 1233-1249
14. Dymock, B. W. and See, C. S. (2013) Inhibitors of JAK2 and JAK3: an update on the patent literature 2010-2012 Expert Opin. Ther. Pat. 23, 449-501
15. Alicea-Velázquez, N. L. and Boggon, T. J. (2011) The use of structural biology in Janus kinase targeted drug discovery Curr. Drug Targets 12, 546-555
16. Lee, J. E., Lee, A. S., Kim, D. H., Jung, Y. J., Lee, S., Park, B.-H., Lee, S. H., Park, S. K., Kim, W., and Kang, K. P. (2012) Janex-1, a JAK3 inhibitor, ameliorates tumor necrosis factor-α-induced expression of cell adhesion molecules and improves myocardial vascular permeability in endotoxemic mice Int. J. Mol. Med. 29, 864-870
17. Cetkovic-Cvrlje, M., Olson, M., and Ghate, K. (2012) Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells Cell Mol. Immunol. 9, 350-60
18. Zak, M., Mendonca, R., Balazs, M., Barrett, K., Bergeron, P., Blair, W. S., Chang, C., Deshmukh, G., DeVoss, J., Dragovich, P. S., Eigenbrot, C., Ghilardi, N., Gibbons, P., Gradl, S., Hamman, C., Hanan, E. J., Harsstad, E., Hewitt, P. R., Hurley, C. A., Jin, T., Johnson, A., Johnson, T., Kenny, J. R., Koehler, M. F. T., Kohli, P. B., Kulagowski, J. J., Labadie, S., Liao, J., Liimatta, M., Lin, Z., Lupardus, P. J., Maxey, R. J., Murray, J. M., Pulk, R., Rodriguez, M., Savage, S., Hia, S., Steffek, M., Ubhayakar, S., Ultsch, M., Abbema, A. V., Ward, S. I., Xiao, L., and Xiao, Y. (2012) Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2 J. Med. Chem. 55, 6176-6193
19. Soth, M., Hermann, J. C., Yee, C., Alam, M., Barnett, J. W., Berry, P., Browner, M. F., Frank, K., Frauchiger, S., Harris, S., He, Y., Hekmat-Nejad, M., Hendricks, T., Henningsen, R., Hilgenkamp, R., Ho, H., Hoffman, A., Hsu, P.-Y., Hu, D.-Q., Itano, A., Jaime-Figueroa, S., Jahangir, A., Jin, S., Kuglstatter, A., Kutach, A. K., Liao, C., Lynch, S., Menke, J., Niu, L., Patel, V., Railkar, A., Roy, D., Shao, A., Shaw, D., Steiner, S., Sun, Y., Tan, S.-L., Wang, S., and Vu, M. D. (2013) 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in in vivo models J. Med. Chem. 56, 345-356
20. Yu, V., Pistillo, J., Archibeque, I., Lee, J., Sun, B.-C., Schenkel, L. B., Geuns-Meyer, S., Liu, L., and Emkey, R. (2013) Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings Exp. Hematol. 41, 491-500
21. Cheng, Y. and Prusoff, W. H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22, 3099-108
22. Frantz, B., Klatt, T., Pang, M., Parsons, J., Rolando, A., Williams, H., Toci, M. J., O'Keefe, S. J., and O'Neill, E. A. (1998) The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding Biochemistry 37, 13846-13853 (Pubitemid 28455562)
23. Anderson, D. R., Meyers, M. J., Vernier, W. F., Mahoney, M. W., Kurumbail, R. G., Caspers, N., Poda, G. I., Schindler, J. F., Reitz, D. B., and Mourey, R. J. (2007) Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2) J. Med. Chem. 50, 2647-2654 (Pubitemid 46896072)
24. Knight, Z. A. and Shokat, K. M. (2005) Features of selective kinase inhibitors Chem. Biol. 12, 621-637 (Pubitemid 43142039)
25. Zapf, C. W., Gerstenberger, B. S., Xing, L., Limburg, D. C., Anderson, D. R., Caspers, N., Han, S., Aulabaugh, A., Kurumbail, R., Shakya, S., Li, X., Spaulding, V., Czerwinski, R. M., Seth, N., and Medley, Q. G. (2012) Covalent inhibitors of interleukin-2 inducible T cell kinase (Itk) with nanomolar potency in a whole-blood assay J. Med. Chem. 55, 10047-10063
26. Thoma, G., Nuninger, F., Falchetto, R., Hermes, E., Tavares, G. A., Vangrevelinghe, E., and Zerwes, H. G. (2011) Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family J. Med. Chem. 54, 284-288
27. Lin, T. H., Hegen, M., Quadros, E., Nickerson-Nutter, C. L., Appell, K. C., Cole, A. G., Shao, Y., Tam, S., Ohlmeyer, M., Wang, B., Goodwin, D. G., Kimble, E. F., Quintero, J., Gao, M., Symanowicz, P., Wrocklage, C., Lussier, J., Schelling, S. H., Hewet, A. G., Xuan, D., Krykbaev, R., Togias, J., Xu, X., Harrison, R., Mansour, T., Collins, M., Clark, J. D., Webb, M. L., and Seidl, K. J. (2010) Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice Arthritis Rheum. 62, 2283-2293
28. Haan, C., Rolvering, C., Raulf, F., Kapp, M., Drückes, P., Thoma, G., Behrmann, I., and Zerwes, H. G. (2011) Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors Chem. Biol. 25, 314-323